Delivery Order SPE2DB24D2003-SPE2DB24FXFP1

Award Date 7/15/24
Potential Completion Date 7/16/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $31,119.15, is a delivery order for the supply of Dupixent 300 mg/2 ml pens. The contract has a firm fixed price pricing type and runs through June 5, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,628.46, is for the delivery of Dupixent 300 mg/2 ml pens. The contract is a Firm Fixed Price Delivery Order with a completion date of June 28, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $14,333.97, is for the delivery of Dupixent 300 mg/2 ml pens. The contract is a firm fixed-price delivery order with a completion date of May 9, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) worth $999,999,999 with the DLA Troop Support Medical, which serves as a primary...
This federal contract award from the Defense Logistics Agency (DLA) is a Firm Fixed Price Delivery Order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml pens. The award, valued at $18,157.04, has an ultimate completion date of November 26, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $16,789.41, is for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of March 12, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $14,935.47 and is a Firm Fixed Price Delivery Order to provide Dupixent 300 mg/2 ml pens. The contract has an ultimate completion date of March 18, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,491.50, is a Firm Fixed Price Delivery Order to supply Dupixent 300 mg/2 ml pens. The contract has an ultimate completion date of December 3, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $13,720.20 firm fixed-price delivery order contract is for the supply of Dupixent 300 mg/2 ml pens. The contract has an ultimate completion date of May 21, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,619.72, is a delivery order for Dupixent 300 mg/2 ml pens, a specialty pharmaceutical product. The contract has an ultimate completion date of July 29, 2024 and uses a firm fixed price pricing type. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,818.18, is for the delivery of Dupixent 300 mg/2 ml pens. It is a firm fixed-price delivery order contract, with a completion date of January 30, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
  • SPE2DB24D2003
    Indefinite Delivery Contract
  • SPE2DB24D2003-SPE2DB24FXFP1
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml pens. The contract is a Delivery Order valued at $14,650.16 with a completion date of July 16, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 10:14 AM